Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial.

Saved in:
Bibliographic Details
Title: Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial.
Authors: Abdel Jawad, Mohammad1,2 (AUTHOR), Furtado, Remo H. M.3 (AUTHOR), Esterline, Russell4 (AUTHOR), Oscarsson, Jan5 (AUTHOR), Gasparyan, Samvel B.6 (AUTHOR), Koch, Gary G.7 (AUTHOR), Martinez, Felipe8 (AUTHOR), Mukhtar, Omar9 (AUTHOR), Verma, Subodh10,11,12 (AUTHOR), Langkilde, Anna Maria5 (AUTHOR), Ambery, Philip5 (AUTHOR), Patel, Shachi1,2 (AUTHOR), Gosch, Kensey1,2 (AUTHOR), Windsor, Sheryl L.1 (AUTHOR), Soares, Ronaldo V. P.13 (AUTHOR), Moia, Diogo D. F.13 (AUTHOR), Aboudara, Matthew14 (AUTHOR), Javaheri, Ali15 (AUTHOR), Saraiva, J. F. Kerr16 (AUTHOR), Maia, Lilia Nigro17 (AUTHOR)
Source: Cardiovascular Diabetology. 7/30/2025, Vol. 24 Issue 1, p1-12. 12p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:14752840
DOI:10.1186/s12933-025-02875-6